المؤلفون: Holmstroem, Rikke B., Pedersen, Sidsel, Jurlander, Rebecca, Madsen, Kasper, Donia, Marco, Ruhlmann, Christina H., Schmidt, Henrik, Haslund, Charlotte A., Bastholt, Lars, Svane, Inge Marie, Ellebaek, Eva

المصدر: Holmstroem , R B , Pedersen , S , Jurlander , R , Madsen , K , Donia , M , Ruhlmann , C H , Schmidt , H , Haslund , C A , Bastholt , L , Svane , I M & Ellebaek , E 2024 , ' Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma ' , European Journal of Cancer , vol. 202 , 114023 . https://doi.org/10.1016/j.ejca.2024.114023Test

مصطلحات موضوعية: Adjuvants, Immunologic/therapeutic use, Humans, Immunotherapy/methods, Ipilimumab/adverse effects, Melanoma/drug therapy, Nivolumab/adverse effects, Skin Neoplasms/drug therapy, Anti-PD-1, Melanoma, Melanoma recurrence, Pembrolizumab, Adjuvant immunotherapy, Nivolumab

وصف الملف: application/pdf

العلاقة: https://vbn.aau.dk/da/publications/12bbdaec-46f2-4403-b474-7b9043a316a4Test

الإتاحة: https://doi.org/10.1016/j.ejca.2024.114023Test
https://vbn.aau.dk/da/publications/12bbdaec-46f2-4403-b474-7b9043a316a4Test
https://vbn.aau.dk/ws/files/703287248/Holmstroem_et_al._2024_._Outcome_of_adjuvant_immunotherapy_in_a_real-world_nation-wide_cohort_of_patients_with_melanoma.pdfTest
http://www.scopus.com/inward/record.url?scp=85188441751&partnerID=8YFLogxKTest

المساهمون: Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim, Kim, Do Young

مصطلحات موضوعية: Antineoplastic Agents* / adverse effects, Carcinoma, Hepatocellular* / pathology, Humans, Liver Neoplasms* / pathology, Middle Aged, Nivolumab / adverse effects, Phenylurea Compounds / adverse effects, Sorafenib / adverse effects, Treatment Failure

العلاقة: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY; J00821; OAK-2022-10721; OAK-2022-10722; OAK-2022-10723; OAK-2022-10724; OAK-2022-10725; OAK-2022-10726; OAK-2022-10727; OAK-2022-10728; https://ir.ymlib.yonsei.ac.kr/handle/22282913/193516Test; https://journals.lww.com/eurojgh/Fulltext/2023/02000/Sorafenib_versus_nivolumab_after_lenvatinib.7.aspxTest; T202300160; EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol.35(2) : 191-197, 2023-02

الإتاحة: https://doi.org/10.1097/MEG.0000000000002466Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193516Test
https://journals.lww.com/eurojgh/Fulltext/2023/02000/Sorafenib_versus_nivolumab_after_lenvatinib.7.aspxTest

المؤلفون: Greve, Patrick, Beishuizen, Auke, Hagleitner, Melanie, Loeffen, Jan, Veening, Margreet, Boes, Marianne, Peperzak, Victor, Diez, Claudius, Meyer-Wentrup, Friederike

المساهمون: Unit Opleiding Aios, Infection & Immunity, CTI Boes, PMC Medisch specialisten, Zorg en O&O, Child Health, CTI Peperzak, Cancer

مصطلحات موضوعية: Bendamustine Hydrochloride/adverse effects, Brentuximab Vedotin/therapeutic use, Child, Hodgkin Disease/drug therapy, Humans, Nivolumab/adverse effects, Treatment Outcome, targeted therapy, checkpoint inhibition, combination immunotherapy, recurrent/refractory classical Hodgkin lymphoma, oncology, Immunology and Allergy, Immunology, Research Support, Non-U.S. Gov't, Journal Article

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/449798Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/449798Test

المؤلفون: Girard, Nicolas, Ponce Aix, S, Cedres, S, Berghmans, Thierry, Burgers, S, Toffart, Anne-Claire, Phalke, Swati Popat, Janssens, A, Gervais, R, Hochstenbag, M, Cardoso da Silva, M., Burger, I A, Prosch, Helmut, Stahel, R, Xenophontos, E, Pretzenbaher, Y, Neven, A, Peters, S.

المصدر: ESMO Open, 8 (3

مصطلحات موضوعية: Sciences bio-médicales et agricoles, Humans, Male, Female, Middle Aged, Nivolumab -- adverse effects, Ipilimumab -- adverse effects, Thymoma -- drug therapy -- chemically induced, Thymus Neoplasms -- drug therapy -- chemically induced, Progression-Free Survival, immunotherapy, thymic carcinoma, thymoma

وصف الملف: 2 full-text file(s): application/pdf | application/pdf

العلاقة: uri/info:doi/10.1016/j.esmoop.2023.101576; uri/info:pii/S2059-7029(23)00808-6; uri/info:pmid/37285717; uri/info:scp/85161327879; uri/info:pmcid/PMC10265606; https://dipot.ulb.ac.be/dspace/bitstream/2013/362468/5/2023-ESMO-GIRARD.pdfTest; https://dipot.ulb.ac.be/dspace/bitstream/2013/362468/1/doi_346112.pdfTest; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/362468Test

الإتاحة: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/362468Test
https://dipot.ulb.ac.be/dspace/bitstream/2013/362468/5/2023-ESMO-GIRARD.pdfTest

المساهمون: Yoon-Koo Kang, Martin Reck, Paul Nghiem, Yan Feng, Gregory Plautz, Hye Ryun Kim 6, Taofeek K Owonikoko, Narikazu Boku, Li-Tzong Chen, Ming Lei, Han Chang, Wen Hong Lin, Amit Roy, Akintunde Bello, Jennifer Sheng, Kim, Hye Ryun

مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols / adverse effects, Humans, Ipilimumab / adverse effects, Lung Neoplasms* / pathology, Nivolumab / adverse effects, Small Cell Lung Carcinoma* / drug therapy, gastrointestinal neoplasms, genetic markers, immunotherapy, lung neoplasms

العلاقة: JOURNAL FOR IMMUNOTHERAPY OF CANCER; J03617; OAK-2022-10595; https://ir.ymlib.yonsei.ac.kr/handle/22282913/193450Test; T9992022679; JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol.10(4) : e004273, 2022-04

الإتاحة: https://doi.org/10.1136/jitc-2021-004273Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193450Test

المؤلفون: Vano, Yann-Alexandre, Elaidi, Réza, Bennamoun, Mostefa, Chevreau, Christine, Borchiellini, Delphine, Pannier, Diane, Maillet, Denis, Gross-Goupil, Marine, Tournigand, Christophe, Laguerre, Brigitte, Barthélémy, Philippe, Coquan, Elodie, Gravis, Gwenaelle, Houédé, Nadine, Cancel, Mathilde, Huillard, Olivier, Beuzeboc, Philippe, Fournier, Laure, Méjean, Arnaud, Cathelineau, Xavier, Doumerc, Nicolas, Paparel, Philippe, Bernhard, Jean-Christophe, de la Taille, Alexandre, Bensalah, Karim, Tricard, Thibault, Waeckel, Thibaut, Pignot, Géraldine, Braychenko, Elena, Caruso, Stefano, Sun, Cheng-Ming, Verkarre, Virginie, Lacroix, Guillaume, Moreira, Marco, Meylan, Maxime, Bougouïn, Antoine, Phan, Letuan, Thibault-Carpentier, Christelle, Zucman-Rossi, Jessica, Fridman, Wolf Herman, Sautès-Fridman, Catherine, Oudard, Stéphane

المساهمون: Cancer Research and Personalized Medicine - CARPEM Paris, Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie Paris (ARTIC), Institut Mutualiste de Montsouris (IMM), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Lutte contre le Cancer Antoine Lacassagne Nice (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UniCA), Centre Régional de Lutte contre le Cancer Oscar Lambret Lille (UNICANCER/Lille), Université de Lille-UNICANCER, Service d'Oncologie Médicale Centre hospitalier Lyon Sud - HCL, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital Saint-André, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CRLCC Eugène Marquis (CRLCC), UNICANCER, Institut de Cancérologie de Strasbourg Europe (ICANS), Centre Régional de Lutte contre le Cancer François Baclesse Caen (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie du GARD ICG - CHU Nîmes (Instit Cancéro - GARD), Clinique d'Oncologie et de Radiothérapie Tours (CORAD), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Hôpital Foch Suresnes, Service des Explorations Fonctionnelles Physiologiques CHU Toulouse, Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hospices Civils de Lyon (HCL), Nouvel Hôpital Civil de Strasbourg, Les Hôpitaux Universitaires de Strasbourg (HUS), Service de Néphrologie-Dialyse-Transplantation rénale CHU Caen, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), ANR-10-LABX-0015,ImmunoOnco,Immuno-Oncology(2010)

المصدر: ISSN: 1470-2045.

مصطلحات موضوعية: MESH: Antineoplastic Combined Chemotherapy Protocols / adverse effects, MESH: Angiogenesis Inhibitors / adverse effects, MESH: Humans, MESH: Ipilimumab, MESH: Lipase, MESH: Male, MESH: Neoplasm Staging, MESH: Nivolumab / adverse effects, MESH: Prospective Studies, MESH: Protein Kinase Inhibitors / adverse effects, MESH: Sunitinib, MESH: Tumor Microenvironment, MESH: Biomarkers, MESH: Carcinoma, Renal Cell / drug therapy, MESH: Female, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

العلاقة: hal-04072026; https://hal.science/hal-04072026Test; https://hal.science/hal-04072026/documentTest; https://hal.science/hal-04072026/file/Vano%20et%20al.pdfTest

الإتاحة: https://doi.org/10.1016/S1470-2045Test(22)00128-0
https://hal.science/hal-04072026Test
https://hal.science/hal-04072026/documentTest
https://hal.science/hal-04072026/file/Vano%20et%20al.pdfTest

المؤلفون: van Not, Olivier J, de Meza, Melissa M, van den Eertwegh, Alfons J M, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van Breeschoten, Jesper, de Groot, Jan-Willem B, Hospers, Geke A P, Ismail, Rawa K, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Stevense-den Boer, Marion A M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Bonenkamp, Han J, Boers-Sonderen, Marye J, Blokx, Willeke A M, Wouters, Michel W J M, Suijkerbuijk, Karijn P M

المصدر: van Not , O J , de Meza , M M , van den Eertwegh , A J M , Haanen , J B , Blank , C U , Aarts , M J B , van den Berkmortel , F W P J , van Breeschoten , J , de Groot , J-W B , Hospers , G A P , Ismail , R K , Kapiteijn , E , Piersma , D , van Rijn , R S , Stevense-den Boer , M A M , van der Veldt , A A M , Vreugdenhil , G ....

مصطلحات موضوعية: Cohort Studies, Humans, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab/therapeutic use, Melanoma/mortality, Nivolumab/adverse effects, Prospective Studies, Skin Neoplasms/drug therapy

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/4eaf37d0-e9eb-444d-8275-f8aa051f3a33Test

الإتاحة: https://doi.org/10.1016/j.ejca.2022.02.026Test
https://hdl.handle.net/11370/4eaf37d0-e9eb-444d-8275-f8aa051f3a33Test
https://research.rug.nl/en/publications/4eaf37d0-e9eb-444d-8275-f8aa051f3a33Test
https://pure.rug.nl/ws/files/218331244/1_s2.0_S0959804922001241_main.pdfTest

المؤلفون: Albiges, Laurence, Tannir, Nizar M., Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R., Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K., Gurney, Howard, Grimm, Marc Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I., Choueiri, Toni K., Leung, David, Saggi, Shruti Shally, Lee, Chung Wei, McHenry, M. Brent, Motzer, Robert J.

المصدر: Albiges , L , Tannir , N M , Burotto , M , McDermott , D , Plimack , E R , Barthélémy , P , Porta , C , Powles , T , Donskov , F , George , S , Kollmannsberger , C K , Gurney , H , Grimm , M O , Tomita , Y , Castellano , D , Rini , B I , Choueiri , T K , Leung , D , Saggi , S S , Lee , C W , McHenry , M B & Motzer , R J 2022 , ....

مصطلحات موضوعية: Advanced renal cell carcinoma, CheckMate 214, Cytoreductive nephrectomy, Ipilimumab, Nivolumab, Ipilimumab/adverse effects, Humans, Sunitinib/therapeutic use, Male, Nivolumab/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Nephrectomy, Carcinoma, Renal Cell/pathology, Kidney Neoplasms/pathology, Female

العلاقة: https://pure.au.dk/portal/da/publications/firstlineTest-nivolumab-plus-ipilimumab-versus-sunitinib-in-patients-without-nephrectomy-and-with-an-evaluable-primary-renal-tumor-in-the-checkmate-214-trial(52c3e567-a31d-460c-a42f-e67dc985a77c).html

الإتاحة: https://doi.org/10.1016/j.eururo.2021.10.001Test
https://pure.au.dk/portal/da/publications/firstlineTest-nivolumab-plus-ipilimumab-versus-sunitinib-in-patients-without-nephrectomy-and-with-an-evaluable-primary-renal-tumor-in-the-checkmate-214-trial(52c3e567-a31d-460c-a42f-e67dc985a77c).html
http://www.scopus.com/inward/record.url?scp=85118750007&partnerID=8YFLogxKTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202028/pdf/nihms-1883652.pdfTest

المؤلفون: Weiss, David, Cantré, Daniel, Zettl, Uwe K, Storch, Alexander, Prudlo, Johannes

المصدر: Journal of neurology 269(5), 2778-2780 (2021). doi:10.1007/s00415-021-10913-y

مصطلحات موضوعية: info:eu-repo/classification/ddc/610, Aquaporin 4, Autoantibodies, Humans, Immune Checkpoint Inhibitors: adverse effects, Neuromyelitis Optica: diagnostic imaging, Neuromyelitis Optica: drug therapy, Nivolumab: adverse effects

جغرافية الموضوع: DE

العلاقة: info:eu-repo/semantics/altIdentifier/issn/0939-1517; info:eu-repo/semantics/altIdentifier/issn/1432-1459; info:eu-repo/semantics/altIdentifier/issn/0340-5354; info:eu-repo/semantics/altIdentifier/issn/0367-004x; info:eu-repo/semantics/altIdentifier/issn/1619-800X; info:eu-repo/semantics/altIdentifier/pmid/pmid:34841443; info:eu-repo/semantics/altIdentifier/issn/0012-1037; https://pub.dzne.de/record/163458Test; https://pub.dzne.de/search?p=id:%22DZNE-2022-00218%22Test

الإتاحة: https://doi.org/10.1007/s00415-021-10913-yTest
https://pub.dzne.de/record/163458Test
https://pub.dzne.de/search?p=id:%22DZNE-2022-00218%22Test

المؤلفون: Krusche, Martin, Schneider, U., Geisler, C., Keller, S., Stenzel, W., Ohrndorf, S.

المصدر: http://lobid.org/resources/99370671254606441Test#!, 80(9):884-888.

مصطلحات موضوعية: Female [MeSH], Checkpointinhibitoren, Checkpoint inhibitors, Aged [MeSH], Drug-Related Side Effects and Adverse Reactions [MeSH], Myalgia contraction myositis, Humans [MeSH], Fasziitis, Nivolumab/adverse effects [MeSH], Eosinophilia, Myalgie-Kontraktur-Myositis, IrAEs, Myalgia [MeSH], Fasciitis, Kasuistiken, Eosinophilie, Myositis/diagnosis [MeSH], Melanoma/drug therapy [MeSH], Myositis/chemically induced [MeSH]

العلاقة: https://repository.publisso.de/resource/frl:6450820Test; https://doi.org/10.1007/s00393-021-01001-7Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575749Test/

الإتاحة: https://doi.org/10.1007/s00393-021-01001-7Test
https://repository.publisso.de/resource/frl:6450820Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575749Test/